State Street’s Allarity Therapeutics ALLR Stock Holding History

State Street’s Portfolio ALLR Stock Details ALLR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$150K	Hold	137,600	–	–	﹤0.01%	3957
2025 Q4	$149K	Hold	137,600	–	–	﹤0.01%	3968
2025 Q3	$217K	Buy	+137,600	New	+$173K	﹤0.01%	3891
2023 Q1	–	Hold	0	–	-$3.81K	–	4787
2022 Q4	–	Hold	0	–	–	–	4840
2022 Q3	–	Hold	0	–	–	–	4866
2022 Q2	–	Hold	0	–	–	–	4889

Other funds holding ALLR

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

State Street's ALLR Position: Q1 2026 in Review

State Street held its Allarity Therapeutics (ALLR) position steady in Q1 2026 at 137,600 shares worth $150K. The position accounts for ﹤0.01% of the portfolio, ranked #3957.

State Street first reported a position in ALLR in Q3 2025 and has held it in 3 quarters since. The position peaked at $217K in Q3 2025. 14 funds tracked by Wall St. Rank hold ALLR as of Q1 2026.

State Street held 137,600 shares of Allarity Therapeutics worth $150K as of Q1 2026.
State Street left its Allarity Therapeutics share count unchanged in Q1 2026.
Allarity Therapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3957 holding.
State Street first reported a position in Allarity Therapeutics in Q3 2025 and has held it in 3 quarters since.
State Street's Allarity Therapeutics position peaked at $217K in Q3 2025.
14 funds tracked by Wall St. Rank held Allarity Therapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.